Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson's disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Movement Disorders
P9 - Poster Session 9 (5:30 PM-6:30 PM)
5-005

Insulin resistance (IR) is a promising therapeutic target in Parkinson’s disease (PD). Currently, receptor agonists of glucagon-like peptide 1 (GLP-1) are the safest and most reliable means of reducing IR. Liraglutide is a powerful GLP-1 agonist currently approved for treatment of diabetes and obesity.

To test the therapeutic efficacy and safety of the GLP-1 agonist liraglutide in patients with idiopathic PD.

In this single-center, randomized, double-blind, placebo-controlled trial, PD patients received, in addition to regular medications, once-daily self-administered injections of liraglutide (1.2 or 1.8 mg, as tolerated) or placebo in a 2:1 study design for 52 weeks after titration. Primary outcomes included the adjusted difference in the OFF-state Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) part III, non-motor symptoms scale (NMSS) and Mattis Dementia Rating Scale (MDRS-2) at week 54. Efficacy analyses included patients who completed any post-randomization follow-up assessment.

63 patients were enrolled and randomized to liraglutide (n=42) or placebo (n=21). Twelve patients were early withdrawals, 4 of whom completed week 28 evaluation. Primary analysis included 37 active and 18 placebo subjects. At 54 weeks, NMSS scores had improved by 6.6 points in the liraglutide group and worsened by 6.5 points in the placebo group, a 13.1 point adjusted mean difference (p=0.07). MDS-UPDRS part III and MDRS-2 score changes from baseline did not significantly differ between active and placebo. Secondary outcome analysis revealed a significant improvement in MDS-UPDRS part-II scores in the treatment group (-4.1 points, p=0.001). Injection site reactions and gastrointestinal symptoms were common AEs. Eleven serious AEs were reported, none of which related to the study intervention.

Treatment with liraglutide improves critical features of PD, including non-motor symptoms and activities of daily living. These results validate similar outcomes reported with other GLP-1 agonists in PD and offer new strategies to treat the constellation of PD symptoms.

Authors/Disclosures
Michele Tagliati, MD, FAAN (Cedars-Sinai Medical Center)
PRESENTER
Dr. Tagliati has received publishing royalties from a publication relating to health care.
Camille Malatt, MD (Cedars-Sinai Movement Disorders) Dr. Malatt has nothing to disclose.
Tina Wu (Cedars-Sinai Medical Center) Tina Wu has nothing to disclose.
Catherine Bresee (Cedars-Sinai Medical Center - Biostatistics Core) Ms. Bresee has nothing to disclose.
Elliot James Hogg, MD (Cedars-Sinai Medical Center) Dr. Hogg has nothing to disclose.
Jeffrey C. Wertheimer, PhD (Cedars-Sinai Medical Center) Dr. Wertheimer has nothing to disclose.
Echo Tan, MD (Cedars Sinai Medical Center) Dr. Tan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan.
Hayley Pomeroy (Cedars-Sinai Medical Center) Hayley Pomeroy has nothing to disclose.
Gloria Obialisi (Cedars-Sinai Medical Center) Gloria Obialisi has nothing to disclose.